Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia

Summary

Patients with refractory autoimmune thrombocytopenia (ITP) may develop life-threatening bleeding that cannot be immediately controlled by drug administration. To date, there have been no studies conducted to evaluate the efficacy of platelet transfusion alone in such cases. Ten patients with refractory ITP and bleeding or a high bleeding risk were consecutively transfused (one unit/30 min) with apheresis platelet concentrates (APC) without the administration of new drugs. The used APCs (average 3 – 7 units) contained 2.7 × 10¹¹ (medium) platelets and were leukodepleted (≤1 × 10⁶ leukocytes/unit).Platelet serology was performed using standard techniques. Platelet transfusion resulted in an increase in the platelet count to 84 – 157 × 10³/µl, and the cessation of bleeding in all patients without any serious adverse effects. Although platelet counts gradually decreased within a few days post-transfusion, bleeding was stopped in all cases. These findings indicate that consecutive platelet transfusion using APCs is a rapidly effective emergency treatment in patients with refractory ITP.

Keywords

Transfusion medicine - thrombocytopenia - platelet transfusion

• References

• 1 Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
• 2 Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94: 909-913.
• 3 George JN, Woolf SH, Raskob GE. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
• 4 Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005; 56: 425-442.
• 5 Blanchette V, Freedman J, Garvey B. Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol 1998; 35: 36-51.
• 6 Portielje JE, Westendorp RG, Kluin-Nelemans HC. et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-2554.
• 7 Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults. Br J Haematol 2002; 118: 933-944.
• 8 McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997; 126: 307-314.
• 9 Imbach P, Barandun S, d’Apuzzo V. et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 01: 1228-1231.
• 10 Bussel JB, Eldor A, Kelton JG. et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004; 91: 771-778.
• 11 Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med 1980; 31: 509-540.
• 12 Buchanan GR, Scher CS, Button LN. et al. Use of homologous platelet survival in differential diagnoses of chronic thrombocytopenia in childhood. Pediatrics 1977; 59: 45-54.
• 13 Stoll D, Cines DB, Aster RH. et al. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood 1985; 65: 584-588.
• 14 Crosby WH. Editorial: Wet purpura, dry purpura. J Am Med Assoc 1975; 232: 744-745.
• 15 Abrahm J, Ellman L. Platelet transfusion in immune thrombocytopenic purpura. J Am Med Assoc 1976; 236: 1847.
• 16 Baumann MA, Menitove JE, Aster RH. et al. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med 1986; 104: 808-809.
• 17 Carr JM, Kruskall MS, Kaye JA. et al. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986; 80: 1051-1054.
• 18 Chandramouli NB, Rodgers GM. Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia. Am J Hematol 2000; 65: 85-86.
• 19 Yoneoka Y, Tokita K, Yamauchi JI. et al. Successful management for spontaneous intracranial haemorrhage under critical thrombocytopenia (platelets < 1000/mm(3)) due to adolescence-onset idiopathic thrombocytopenic purpura. Acta Neurochir (Wien) 2004; 146: 199-201.
• 20 Bay A, Oner AF, Etlik O. et al. A case of immune thrombocytopenic purpura presenting with recurrent intracranial hemorrhage. Pediatr Int 2005; 47: 109-111.
• 21 Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Blackwell Science Ltd; London: 1997
• 22 Antoine C, Muller S, Cant A. et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet 2003; 361: 553-560.
• 23 Friederich PW, Henny CP, Messelink EJ. et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-205.
• 24 Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-890.
• 25 Minniti C, Weintal J. Use of Recombinant Activated Factor VII (rFVIIa) in Two Children with Idiopathic Thrombocytopenic Purpura (ITP). Blood 2001; 98: 62b.
• 26 Gerotziafas GT, Zervas C, Gavrielidis G. et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002; 69: 219-222.
• 27 Waddington DP, McAuley FT, Hanley JP. et al. The use of recombinant factor viia in a jehovah’s witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 2002; 119: 286-288.
• 28 Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003; 120: 909-910.
• 29 Salama A, Rieke M, Kiesewetter H. et al. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: A review of the literature. Ann Hematol. 2008 prebub online.
• 30 NCI. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. National Cancer Institute, US National Institutes of Health. Available at http://ctepinfonihgov 2006
• 31 Meyer O, Agaylan A, Bombard S. et al. A novel antigen-specific capture assay for the detection of platelet antibodies and HPA-1a phenotyping. Vox Sang 2006; 91: 324-330.
• 32 Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616.
• 33 Stasi R, Evangelista ML, Stipa E. et al. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 2008; 99: 4-13.
• 34 Pruss A, Kalus U, Radtke H. et al. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Transfus Apher Sci 2004; 30: 41-46.
• 35 Salama A, Berghofer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992; 340: 1515-1517.
• 36 Ahrens N, Pruss A, Kahne A. et al. Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion 2007; 47: 813-816.
• 37 Kiefel V, Bassler D, Kroll H. et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006; 107: 3761-3763.
• 38 Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol 2007; 14: 671-676.
• 39 Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006; 355: 1303-1305.